BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,040

Employees3,040

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,040

Employees3,040

BMRN Key Statistics

Market cap

10.20B

Market cap10.20B

Price-Earnings ratio

16.02

Price-Earnings ratio16.02

Dividend yield

—

Dividend yield—

Average volume

1.83M

Average volume1.83M

High today

$54.39

High today$54.39

Low today

$52.94

Low today$52.94

Open price

$54.25

Open price$54.25

Volume

1.83M

Volume1.83M

52 Week high

$78.00

52 Week high$78.00

52 Week low

$52.93

52 Week low$52.93

BMRN News

Simply Wall St 2d

BioMarin: Valuation in Focus After New VOXZOGO and PALYNZIQ Study Results Boost Confidence

Advertisement Most Popular Narrative: 44% Undervalued BioMarin Pharmaceutical (BMRN) just put a major spotlight on its pipeline by revealing fresh results fro...

Simply Wall St 6d

Could Recent Clinical Progress Reshape BioMarin’s Long-Term Competitive Edge in Rare Diseases?

BioMarin Pharmaceutical recently announced new clinical data for VOXZOGO, showing anatomical improvements in spinal morphology in young children with achondropl...

Analyst ratings

83%

of 30 ratings

Buy

83.3%

Hold

16.7%

Sell

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.